Understand The Pros and Cons of Lemtrada RRMS Treatments
Lemtrada is an essential therapy for people who suffer from the most advanced and untreatable stages of relapse-remitting multiple sclerosis
Wednesday, October 16, 2019 - Doctors and patients must understand the benefits and extreme side effects that the drug carries, including causing death. Sanofi, the maker of Lemtrada, has gone to great lengths to educate doctors and patients with RRMS about the facts about the drug. In the end, only the patient can decide if Lemtrada is right for them. If you are considering starting to take Lemtrada, please go to www.Lemtrada.com and read the web site thoroughly. I have done so and below are some of the highlights I think are very important to know.
Sanofi stresses five main points as the basis for understanding Lemtrada (alemtuzumab). The first item to consider is that Lemtrada (alemtuzumab) is for adults only and is a drug of last resort only to be taken when at least two others have failed to control your RRMS symptoms. The second important point is that Lemtrada is administered to RRMS patients in a procedure that you may not have experienced previously. According to Sanofi, Lemtrada "is administered in 8 doses over two years-on 5 consecutive days in round 1 and, one year later, on 3 consecutive days in round 2." Lemtrada lawsuit attorneys representing people and families nationwide, offer a free consultation before filing a claim.
Before starting to receive Lemtrada a patient and their doctor must first sign up and complete the Lemtrada Risk Evaluation and Mitigation Strategy (REMS) program so that everyone knows the risks that include having a paralyzing stroke and sudden death from a heart attack. Doctors will need to check on a Lemtrada patient regularly and to watch for the symptoms that something may be wrong. "(Lemtrada patients) will be monitored monthly starting after the first infusion and continue to monitor until 4 years or longer after the last round of treatment."
The fourth point to consider once the risks have been digested is more positive and encouraging in that 65% of Lemtrada patients "were relapse-free" after 2 years. In an extended study, "79-87% of RRMS patients were relapse-free from 3-6 years." Finally, if you and your doctor agree that Lemtrada is the right treatment for you, Sanofi makes a package of financial assistance available to you.
It is critical that both the doctor and patient know the early warning signs of Lemtrada's potentially deadly side effects in advance and diligently watch for them both during and after treatments. Lemtrada causes kidney problems which can lead to kidney damage and failure requiring dialysis and eventually a kidney transplant. Watch for "swelling of your legs or feet; blood in the urine (red or tea-colored urine); decrease in urine; fatigue; coughing up blood," according to Sanofi. Lemtrada also causes blood clotting problems called "Immune thrombocytopenic purpura (ITP), a condition of reduced platelet counts in your blood that can cause severe bleeding that may cause life-threatening problems." Symptoms of ITP are "easy bruising; bleeding from a cut that is hard to stop; coughing up blood; heavier menstrual periods than normal; bleeding from your gums or nose that is new or takes longer than usual to stop; small, scattered spots on your skin that are red, pink, or purple."
More Recent Lemtrada Stroke Lawsuit News:
- Lemrtrada Risks Were Worth It For One Recent Patient | 4/14/2021
- The Shocking Types of Deaths Caused By Lemtrada | 4/9/2021
- RRMS Has Different Stages With Different Symptoms | 4/5/2021
- Nurses Monitor Lemtrada (Alemtuzumab) Patients For Signs of Its Deadly Side Effects | 3/31/2021
- Lemtrada Can Cause Sudden Death And Many Other Health Issues | 3/8/2021
- Lemtrada May Slow the Progression of Relapse Remitting MS But with Potentially Severe Side Effects | 3/5/2021
- MS Doctors May Need To Be Reminded of Lemtrada's Deadly Side Effects | 3/1/2021
- Doctors Treating RRMS Must Discuss Lemtrada's Deadly Side Effects With Patients | 2/23/2021
- Lemtrada Can Cause An Arterial Dissection and Instant Death | 1/20/2021
- Lemtrada Toxicity May Cause Arterial Dissection Leading To Strokes | 1/13/2021
- People As Young As 20 Should Watch For Symptoms of Multiple Sclerosis | 12/30/2020
- Lemtrada Patients Could Be At Risk When Taking Covid-19 Vaccine | 12/15/2020
- Lemtrada Patients Have May Have Safer Options | 12/8/2020
- Stem Cell Rejection Could Complicate Future RRMS Treatments | 11/25/2020
- Breakthroughs In Stem Cell Transplantation Could Eliminate The Need For Lemtrada And Its Unpredictable Side Effects | 11/19/2020
- Lemtrada Patients Should Know Their Life Is In Danger By Taking Lemtrada | 11/9/2020
- Lemtrada Patients May Try Anything To Keep Multiple Sclerosis In Check | 11/4/2020
- Lemtrada Offers Hope For Those With Advanced RRMS | 10/13/2020
- Lemtrada Sometimes Works Well But Patients Were Only Recently Warned About The Dangers of The Drug | 10/6/2020
- Drugs Like Lemtrada May Benefit MS Patients Right From The Start | 9/29/2020
- Multiple Sclerosis Patients Suffer Fatigue Before Symptoms Gradually Increase | 9/23/2020
- Doctors May Have Dropped Lemtrada Over Covid-19 Fears | 9/2/2020
- Relapse Remitting Multiple Sclerosis Patients May Have a Promising New Drug | 8/25/2020
- Ofatumumab Could Replace Lemtrada For Treatment of Multiple Sclerosis | 8/8/2020
- RRMS Patients Have A Great Source of Information That Can Help Them Deal With Every Aspect of Their Disease | 8/4/2020
- New Information About COVID19 and Taking Lemtrada | 7/16/2020
- The Risks Of Lemtrada Therapy And Other DMTs | 7/9/2020
- Lemtrada Patients Face Possibility Of Living With The After-Effects of a Stroke | 7/6/2020
- A Multiple Sclerosis Doctor Explains The Ins and Outs of Lemtrada for RRMS Patients in a Series of YouTube Videos | 6/22/2020
- Lemtrada Carries Serious Side Effects That Come With The Potential Relief The Drug Offers | 6/1/2020
- Canadians Have One of the World's Highest Rates of Multiple Sclerosis | 5/28/2020
- RRMS Patients Explain Difficulty Managing The Disease During The Covid-19 Pandemic | 5/21/2020
- Relapse Remitting Multiple Sclerosis Patients Share Their Lemtrada Experiences Online | 5/12/2020
- Lemtrada May Also Cause ANCA Vasculitis | 4/27/2020
- Relapse Remitting Multiple Sclerosis Patients (RRMS) Should First Try Telephoning Their Doctors Before Risking Going To The Hospital Directly | 4/22/2020
- Experts Weigh In On Discontinuing Lemtrada Treatments During Pandemic | 4/10/2020
- Lemtrada Patients At Extreme Risk From COVID-19 | 4/8/2020
- Relapse-Remitting Multiple Sclerosis Patients Should Avoid Lemtrada (alemtuzumab) During The Covid-19 Pandemic | 3/20/2020
- Sanofi Forced To Pay $11.8 Million In Alleged Kick-Back Scheme | 3/16/2020
- Newly Diagnosed RRMS Patients Should Avoid Lemtrada and Look to Other Less Toxic Treatments | 3/11/2020
- Lemtrada Deaths Prompt Greater Scrutiny and Harsher Warnings | 2/27/2020
- Lemtrada Patients Dying At An Alarming Rate | 2/10/2020
- Lemtrada Patients Report Positive Experiences From Taking The Anti-MS Drug | 2/4/2020
- Lemtrada Fears May Be Overdone | 1/30/2020
- Some Patients Rave About Lemtrada's Effectiveness While Others Are Left Permanently Disabled | 1/8/2020
- One Last Lemtrada Warning for 2019 | 1/2/2020
- RRMS Patients May Try Stem Cell Therapy if Lemtrada Fails | 12/26/2019
- Lemtrada Patient's Fear of the Unknown Moderated in YouTube Testimonial Videos | 12/16/2019
- Lemtrada Side Effect Awareness Requirements | 12/11/2019
- Lemtrada is serious medication for a serious condition | 11/21/2019
- More Restrictions Placed on Multiple Sclerosis Sufferers Who Wish to Receive Lemtrada Treatment | 11/15/2019
- RRMS Patients May Look To Alternatives To Lemtrada | 11/6/2019
- Europe's Medicine Agency Increases Lemtrada Restrictions | 11/4/2019
- Lemtrada Is More Deadly Than Originally Thought | 10/10/2019
- Obesity Can Make Multiple Sclerosis Medications Less Effective | 10/2/2019
- RRMS Patients Should Consider Lemtrada's Risk of Arterial Dissection | 9/18/2019
- Multiple Sclerosis Patient Have a Difficult Decision To Make When The Disease is in its Latter Stages | 9/6/2019
- Lemtrada's Deadly Side Effects Greater Than Previously Thought | 9/2/2019
- Drug Makers Look to Mitigate Lemtrada's Life-Threatening Side Effects | 8/26/2019
- Lemtrada Relieves RRMS Symptoms Allowing Patients to Enjoy a Better Quality of Life | 8/20/2019
- Lemtrada Causes High Blood Pressure Before a Stroke Occurs | 8/6/2019
- Lemtrada Patients Report Promising Results | 8/1/2019
- The European Medicines Agency is Studying Lemtrada's Side Effects | 7/30/2019
- What To Watch For Indicating You May Have Multiple Sclerosis | 7/10/2019
- Lemtrada May Be Twice as Effective As Its Leading Competitor | 7/5/2019
- Brain Bleeding May Indicate a Lemtrada Stroke is Imminent | 6/27/2019
- Treating Multiple Sclerosis From Many Angles | 6/21/2019
- Lemtrada's Risks Exceed The Black Box Warning | 6/18/2019
- A Long-Term Study Demonstrates Lemtrada's Effectiveness and Adverse Side Effects | 6/11/2019
- A Leading Authority Finds Lemtrada Causes Brain Bleeding | 5/30/2019
- Lemtrada's Incredibly Long List of Adverse Side Effects | 5/23/2019
- The Outlook is Grim For Relapsing-Remitting Multiple Sclerosis (RRMS) Patients | 5/15/2019
- Lemtrada Forced To Update Black Box Warning To Include Chance of Stroke | 5/10/2019
- The European Medicines Agency Urges Doctors To Stop Using Lemtrada Effective Immediately | 5/4/2019
- The Pros and Cons of Lemtrada Therapy | 4/19/2019
- Europe's FDA is Reviewing Lemtrada's Stroke Side Effect | 4/15/2019
- Lemtrada is a drug that is approved for patients suffering from relapsing multiple sclerosis but can have serious and often deadly side effects. | 4/9/2019
- MS Doctors Must Weigh The Benefits of Lemtrada Versus The Drug's Stroke Risks | 4/3/2019
- Individuals Suffering From RLMS Now Have a New Drug Called Mavenclad That Can Help Alleviate Seizures | 4/1/2019
- Stroke Warning Added to Lemtrada Boxed Label | 3/28/2019
- Anti MS Drug Lemtrada Carries Multiple Lethal Side Effects | 3/25/2019
No-Cost, No-Obligation Lemtrada Lawsuit Case Review If You or a Loved One Suffered from Lemtrada Stroke Complications
OnderLaw, LLC is a St. Louis personal injury law firm handling serious injury and death claims across the country. Its mission is the pursuit of justice, no matter how complex the case or strenuous the effort. The Onder Law Firm has represented clients throughout the United States in pharmaceutical and medical device litigation such as Pradaxa, Lexapro and Yasmin/Yaz, where the firm's attorneys held significant leadership roles in the litigation, as well as Actos, DePuy, Risperdal and others. The Onder Law Firm has won more than $300 million in four talcum powder ovarian cancer lawsuits in St. Louis. Law firms throughout the nation often seek its experience and expertise on complex litigation.